Haleon completed the acquisition of the remaining 12% stake in Tianjin TSKF Pharmaceutical for $222m.

Synopsis

Haleon, a British multinational consumer healthcare company, completed the acquisition of the remaining 12% stake in Tianjin TSKF Pharmaceutical, a pharmaceutical company, for $222m.

Principals

target

Tianjin Tskf Pharmaceutical

bidder

HALEON

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

Market Context